FDA Approves New Injectable Drug to Treat Schizophrenia

The FDA approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is administered by a health care professional every four to six weeks using an injection in the arm or buttocks, according to the agency.

Enable Injections Introduces Mobile Monitoring and Larger Volume Capabilities to its Compact-Sized Wearable Injectors

Enable Injections, the developer and manufacturer of a new wearable injector technology platform that allows patients to comfortably self-administer large volume drugs subcutaneously, announced two major technology advances.

First, the company states its now offers an Enable Wearable Injector with Bluetooth connectivity for compliance monitoring and big data capture with a mobile app.

Mylan Launches Generic Unasyn for Injection

Mylan announced the U.S. launch of Ampicillin and Sulbactam for injection USP, 1.5 g/vial (1 g Ampicillin as the Sodium Salt and 0.5 g Sulbactam as the Sodium Salt), and 3 g/vial (2 g ampicillin as the sodium salt plus 1 g sulbactam as the sodium salt), and 15 g, Pharmacy Bulk Package, (10 g Ampicillin as the Sodium Salt and 5 g Sulbactam as the Sodium Salt), the generic version of Pfizer's Unasyn. 

St-Hubert Restaurants to Stock Allerject Epinephrine Auto-Injectors

The St-Hubert restaurant chain is teaming up with Sanofi Canada to stock Allerject epinephrine auto-injectors in all of its 117 locations in Quebec, Ontario, and New Brunswick, the company announced.

ChiRhoClin Inc. Announces Secretin Drug Shortage Resolved

ChiRhoClin received notice that its contract manufacturing facility has been approved to develop ChiRhoStim, a human secretion for injection, for the next 10 years. The company says it worked with the FDA, the Drug Shortage Team, and the Office of Pharmaceutical Quality to resolve the shortage.

"With the FDA approval of ChiRhoClin's contract manufacturer, we can once again provide an uninterrupted supply of ChiRhoStim to the medical community,” says Dr. Skip Purich, chief operating officer of ChoRhoClin Research Institute (CRI).

Novo Nordisk’s FlexPro PenMate Hides Needle During Injection

Novo Nordisk announced the FDA’s approval of FlexPro PenMate, designed for users of Norditropin FlexPro 5 mg, 10 mg, and 15 mg pens who dislike needles and prefer them to be hidden during the injection process. 

West Pharma Expands Arizona Manufacturing Facility

The Scottsdale, AZ facility of West Pharmaceutical Services Inc. expanded to meet increased customer demand for the SmartDose Electronic Wearable Injector. 

“Expanding our manufacturing capabilities in Scottsdale – and continuing scaling up production in Israel – will enable rapid, dual sourcing to our customers and help them bring innovative new treatments to market,” says Eric Resnick, president of pharmaceutical delivery systems, proprietary products at West, in a released statement.

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

Hospira Inc. has received the FDA’s approval to launch bivalirudin for injection, which is a generic version of The Medicines Company’s Angiomax.

It is available in single-dose flip-top vial, and the company plans to launch a differentiated presentation of the 250-mg bivalirudin for injection in Hospira’s ADD-Vantage vial. 

West Pharma Celebrates Groundbreaking of Waterford, Ireland Manufacturing Facility

West Pharmaceutical Services hosted a groundbreaking ceremony in Waterford, Ireland, to mark the start of construction for the company's new pharmaceutical component manufacturing facility.

The facility will manufacture packaging components for insulin injector cartridges and other high-value packaging components for injectable drugs in order to meet increasing customer demand, according to a press release. West Pharma intends to employ approximately 150 people in engineering, production and other positions by the commencement of operations in late 2018.

Ypsomed, Sanofi Partnership to Take on Added Injection System Production Line Late 2016

Pharmaceutical group Sanofi and the Ypsomed Group announced a new project to add to its longstanding partnership. Ypsomed will begin manufacturing injection system components on an additional dedicated production line starting in late 2016.

Syndicate content